Recent updates

Pfizer to acquire Biohaven Pharma for $11.6 billion

Posted on11 May 2022

TagsBiohaven, Nurtec ODT, pfizer, Pfizer strategic deal, Rimegepant, Zavegepant

Comments0

Pfizer entered into a definitive agreement under which Pfizer will acquire Biohaven for 11.6 billion $. Biohen is the maker of Nurtec ODT, an innovative dual-acting migraine therapy approved for...

Aurobindo Pharma acquires Veritaz Healthcare

Posted on31 Mar 2022

Tagsacquisistion in pharma, acquisition, Aurobindo, Veritaz Healthcare

Comments0

Aurobindo Pharma Ltd has announced the acquisition of the domestic formulation business of Veritaz Healthcare for a consideration of Rs. 171 crore on debt-free cash-free basis. With this acquisition, Aurobindo...

Sun Pharma to launch Vortioxetine in India

Posted on31 Mar 2022

TagsLundbeck, Sun Pharma, vortioxetine

Comments0

Sun Pharma has entered into an exclusive patent licensing agreement with H. Lundbeck A/S (“Lundbeck”) to market and distribute its own version of Vortioxetine in India under the brand name,...

Is HEOR and Market Access is same?

Posted on24 Mar 2022

TagsHEOR, market access

Comments0

HEOR and market access are the two separate domain or functional area within pharmaceutical organization. But they work for the same or similar objective. Both are having objective to gain...

Case Study : US FDA approval of Marinus Pharma’s Ztalmy

Posted on22 Mar 2022

Tagsganaxolone, Ztalmy

Comments0

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced that the US Food and Drug Administration (FDA) has approved Ztalmy (ganaxolone)...

Lynk Pharma, Simcere licensing deal for development of novel JAK1 inhibitor LNK01001 in China

Posted on21 Mar 2022

TagsJAK inhibitor, JAK1 inhibitor

Comments0

Lynk Pharmaceuticals Co., Ltd. and Simcere announced a strategic partnership to develop and commercialize a highly selective JAK1 inhibitor LNK01001 in China. Under the terms of the agreement, Lynk Pharmaceuticals...

What if Design of experiments (DoE) approach?

Posted on21 Mar 2022

Comments0

Design of experiments (DoE) is a systematic approach aiming to maximize information content from an experimental study, while keeping the number of experiments low. During formulation development, DoE is used...

Torrent Pharma to manufacture and sell Pfizer’s Paxlovid generic

Posted on21 Mar 2022

TagsCOVID-19, paxlovid, pfizer

Comments0

Torrent Pharmaceuticals Limited (TPL) has announced that it has signed a non-exclusive, non-transferable, non-sub licensable, license agreement to use the patents and know-how in relation to the compound nirmatrelvir with...

Insight on AstraZeneca’s global R&D Postdoctoral Challenge initiative

Posted on19 Mar 2022

TagsAstraZeneca, research and development in pharma

Comments0

AstraZeneca launched a global R&D Postdoctoral Challenge to help accelerate ideas to transform the treatment of some of the world’s most complex diseases. AstraZeneca launches this initiative at EXPO 2020...

Case Study: Pfizer’s Arena acquisition – A $6.7B deal

Posted on20 Dec 2021

Tagsacquisition, acquisition in pharma, largest ever pharma deal, pfizer, Pfizer strategic deal, pharma acquisition, pharma deal, pharma strategic deal

Comments0

Pfizer will acquire Arena Pharmaceuticals for $6.7 billion to expand its pipeline of immuno-inflammatory disease drugs in development. Why Pfizer acquired Arena? The proposed acquisition of Arena complements Pfizer’s capabilities...

Zydus gets orphan drug designation from USFDA for antimalarial compound

Posted on17 Dec 2021

TagsZydus cadila

Comments0

Zydus Cadila said its antimalarial compound ZY19489′, which is currently under development with Medicines for Malaria Venture (MMV), has received ‘orphan drug designation’ from the US FDA. The orphan drug...

Keros Therapeutics Strategic deal with Hansoh Pharma for Rights to KER-050 in China

Posted on17 Dec 2021

TagsHansoh Pharmaceutical Group, Keros Therapeutics

Comments0

Keros Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need,...

Case Insight: Natco acquires Dash Pharmaceuticals

Posted on17 Dec 2021

Tagsacquisition, acquisition in pharma, brand acquisition, Natco, pharma acquisition, pharma deal

Comments0

NATCO Pharma, through its affiliates, is proposing to enter into an agreement to acquire Dash Pharmaceuticals LLC subject to satisfactory completion of due diligence, execution of definitive agreements and compliance...

Cadila launches ayurvedic energy tonic Healtherbs

Posted on10 Dec 2021

TagsCadila, Cadila Healthcare, Healtherbs, What is Nutraceuticals?

Comments0

Drug major Cadila Pharmaceuticals has introduced an ayurvedic general health tonic that helps keep the body young, active and fit. The key ingredients of Healtherbs include Gokhru (Tribulus terrestris), Ashwagandha...

Aqilion buys rights to Phase-I ready anti-inflammatory program from LEO Pharma

Posted on06 Dec 2021

TagsAqilion, JAK1 inhibitor, leo pharma, Regulus

Comments0

Swedish life science company Aqilion has acquired all rights to Regulus, a Phase I-ready anti-inflammatory program, from Denmark-headquartered dermatology specialist LEO Pharma, which developed the project from early internal discovery...

SPARC entered into a licensing agreement with Biomodifying

Posted on06 Dec 2021

Tagsbiopharmaceuticals, global pharma deals, licensing deal in pharma, SPARC, Sun Pharma, Sun Pharma Advanced Research Company (SPARC) has out-licensed Xelpros to a subsidiary of Sun Pharma for the US market

Comments0

Sun Pharma Advanced Research Company (SPARC) has entered into a licensing agreement with Biomodifying to acquire exclusive rights for antibody against unique oncology target. Biomodifying, LLC is a biotech company...

Pharma Case Study: Merck’s $11.5B acquisition of Acceleron

Posted on03 Oct 2021

TagsAcceleron, Luspatercept, MARKET EXCLUSIVITY, Merck, Reblozyl, sotatercept

Comments0

Merck will acquire Acceleron Pharma, Inc. XLRN for $180 per share in cash for an approximate total equity value of $11.5 billion in a bid to build its rare diseases...

Sanofi Bangladesh Limited’s majority stake is acquired by Beximco Pharma, Bangladesh

Posted on03 Oct 2021

TagsBangladesh pharma, Beximco Pharmaceuticals, Sanofi

Comments0

Beximco Pharmaceuticals Limited, one of leading pharmaceutical company based at Bangladesh, have completed its acquisition of the majority stake (54.6%) in Sanofi Bangladesh Limited. About Sanofi Bangladesh Sanofi Bangladesh is...

What are the difference between Wholesaler and Specialty Pharmacy?

Posted on07 Sep 2021

Comments0

There are clear cut difference between the two terms. The wholesalers are the first purchaser of the drug, directly from manufacturer. Specialty pharmacy involves in distribution of the high cost...

Pfizer to acquire Biohaven Pharma for $11.6 billion

Aurobindo Pharma acquires Veritaz Healthcare

Sun Pharma to launch Vortioxetine in India

Is HEOR and Market Access is same?

Case Study : US FDA approval of Marinus Pharma’s Ztalmy

Lynk Pharma, Simcere licensing deal for development of novel JAK1 inhibitor LNK01001 in China

What if Design of experiments (DoE) approach?

Torrent Pharma to manufacture and sell Pfizer’s Paxlovid generic

Insight on AstraZeneca’s global R&D Postdoctoral Challenge initiative

Case Study: Pfizer’s Arena acquisition – A $6.7B deal

Zydus gets orphan drug designation from USFDA for antimalarial compound

Keros Therapeutics Strategic deal with Hansoh Pharma for Rights to KER-050 in China

Case Insight: Natco acquires Dash Pharmaceuticals

Cadila launches ayurvedic energy tonic Healtherbs

Aqilion buys rights to Phase-I ready anti-inflammatory program from LEO Pharma

SPARC entered into a licensing agreement with Biomodifying

Pharma Case Study: Merck’s $11.5B acquisition of Acceleron

Sanofi Bangladesh Limited’s majority stake is acquired by Beximco Pharma, Bangladesh

What are the difference between Wholesaler and Specialty Pharmacy?

Biopharma Selling Skill Training

Executive Program in Biopharma Business Development and Strategic Management

KPE-C-062 KPE’s Certificate Course in Selling Skills for Medical Representatives

KPE-C-080 Certificate Course in Pharma Business Development & Licensing

KPE-C-079 KPE’s 1 Week Fundamental Training on Drug Discovery to Commercialization Pathway

KPE-C-077 – Fundamental Training on Data Integrity in pharmaceutical and biopharmaceutical industry

KPE-C-064N KPE’s 1 Month Certificate Course in Pharma Sales Management

KPE-C-103 Executive Program in Global Drug Regulatory Affairs [EPGDRA]

Fundamental Training on Pharma Marketing Plan Development

KPE-C-074 Fundamental Training on Monoclonal Antibody

KPE-C-073 Fundamental Training on Regulatory Affairs Advance Strategic Planning

KPE-C-072 Fundamental Training on 505B(2) Application Submission

Your form has been submitted

Recent updates

Please sign in first

Not a member?

Please sign in first

Not a member?

Please sign in first

Not a member?

Please sign in first

Not a member?

Please sign in first

Not a member?

Please sign in first

Not a member?

Please sign in first

Not a member?

Please sign in first

Not a member?

Please sign in first

Not a member?

Please sign in first

Not a member?

Please sign in first

Not a member?

Please sign in first

Not a member?